Casale F, D'Angelo V, Addeo R, Caraglia M, Crisci S, Rondelli R, Di Tullio M T, Indolfi P
Pediatric Oncology Service, Pediatric Department, II University of Naples, 80138 Napoli, Italy.
Oncol Rep. 2004 Dec;12(6):1201-7. doi: 10.3892/or.12.6.1201.
Little is known about the prognostic role of multidrug resistance (MDR) in newly diagnosed childhood acute lymphoblastic leukemia (ALL). P-glycoprotein 170 (MDR1), a cellular drug efflux pump, is thought to be one of the major causes of MDR. The aim of this retrospective study was to evaluate in 85 children with ALL the impact of the MDR1 product of the mdr-1 gene on the achievement of complete remission (CR) and outcome. MDR1 protein expression was performed by immunocytochemistry (ICC), and flow cytometry (FC). MDR1 functional activity was performed by a rhodamine (Rhd)-123 efflux test with or without verapamil. All patients enrolled in our study were treated with AIEOP ALL 91-95 protocols. At diagnosis, 40 patients (47%) expressed MDR1 protein at significant levels, and 45 (53%) were MDR1 negative. Forty-three of the latter patients were also negative for MDR1 function, while 34/40 (85%) patients MDR1 positive preserved the function. Rhd-123 efflux was inhibited by the MDR modulator verapamil in 12/40 (30%) patients. After induction treatment, CR was achieved in 77/85 children (90.6%). All patients who did not achieve CR were MDR1 positive. Twenty-nine patients relapsed, 17 (58.6%) of whom were MDR1 positive. The 10-year overall survival (OS) rate, and disease-free survival (DFS) for MDR1 negative patients compared to MDR1 positive patients were 75.7% versus 54.8%, and 67.5% versus 46%, respectively. The 10-year event-free survival (EFS) rate was significantly higher (67.5% versus 36.8%) in the MDR1 negative group compared with the MDR1 positive population (p=0.001). Multivariate analysis showed that only EFS was independent of age, WBC count, immunophenotype, FAB subtype and prednisone response (p=0.019). Our results, derived from a monocentric study, demonstrate that MDR1 expression in childhood ALL is an independent adverse prognostic factor on outcome, and could be a useful biological marker of response in these patients. Moreover, MDR1 function was also a predictor of response, but only in univariate analysis.
关于多药耐药(MDR)在新诊断的儿童急性淋巴细胞白血病(ALL)中的预后作用,人们所知甚少。P-糖蛋白170(MDR1),一种细胞药物外排泵,被认为是MDR的主要原因之一。这项回顾性研究的目的是评估85例ALL患儿中mdr-1基因的MDR1产物对完全缓解(CR)的实现和预后的影响。通过免疫细胞化学(ICC)和流式细胞术(FC)检测MDR1蛋白表达。通过罗丹明(Rhd)-123外排试验,在有或没有维拉帕米的情况下检测MDR1功能活性。我们研究中纳入的所有患者均采用AIEOP ALL 91 - 95方案进行治疗。诊断时,40例患者(47%)高水平表达MDR1蛋白,45例(53%)为MDR1阴性。后一组患者中有43例MDR1功能也为阴性,而40例MDR1阳性患者中有34例(85%)保留了该功能。在40例患者中有12例(30%)的Rhd - 123外排被MDR调节剂维拉帕米抑制。诱导治疗后,85例患儿中有77例(90.6%)实现了CR。所有未实现CR的患者均为MDR1阳性。29例患者复发,其中17例(58.6%)为MDR1阳性。MDR1阴性患者与MDR1阳性患者相比,10年总生存率(OS)分别为75.7%和54.8%,无病生存率(DFS)分别为67.5%和46%。MDR1阴性组的10年无事件生存率(EFS)显著高于MDR1阳性组(67.5%对36.8%,p = 0.001)。多变量分析显示,只有EFS独立于年龄、白细胞计数、免疫表型、FAB亚型和泼尼松反应(p = 0.019)。我们来自单中心研究的结果表明,儿童ALL中的MDR1表达是预后的一个独立不良预测因素,并且可能是这些患者反应的一个有用生物标志物。此外,MDR1功能也是反应的一个预测指标,但仅在单变量分析中如此。